Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Etanercept; Methotrexate

Criteria

Inclusion Criteria:

• Diagnosis of early rheumatoid arthritis.

• Methotrexate (MTX) naive.

• Active early rheumatoid arthritis at the time of enrollment.

Exclusion Criteria:

• Previous or current treatment with etanercept, other tumor necrosis factor-alpha (TNF) inhibitors, or other biologic agents.

• Concurrent treatment with any disease-modifying anti-rheumatoid drugs (DMARD), within 4 weeks before baseline.

• Concurrent treatment with more than 1 non-steroidal anti-inflammatory drug (NSAID) at baseline.